Colgate-Palmolive Prepares for Q1 Earnings Report with Positive Outlook

Founded in 1806 and based in New York, Colgate-Palmolive Company (CL) is a leader in the consumer products sector, with a market cap of $76.2 billion. The company operates globally through two main segments: Oral, Personal, and Home Care; and Pet Nutrition. Its portfolio includes well-known brands such as Colgate, Palmolive, Darlie, elmex, hello, meridol, and Sorriso.

Upcoming Q1 Earnings Expectations

Colgate-Palmolive is set to report its Q1 earnings on Friday, April 25, before the market opens. Analysts project an EPS of $0.87 per share for the quarter, marking a 1.2% increase from the $0.86 reported during the same period last year. Over the last four quarters, CL has consistently surpassed earnings estimates, showcasing its resilience in the marketplace.

Performance and Future Projections

In its most recent quarter, Colgate-Palmolive’s adjusted EPS reached $0.91, exceeding analysts’ expectations by 2.3%. This growth reflects strong demand for its branded consumer products. Looking ahead, analysts forecast an adjusted EPS of $3.70 for fiscal 2025, up 2.8% from $3.60 in fiscal 2024. Furthermore, fiscal 2026 is projected to see an 8.1% year-over-year growth in adjusted EPS, reaching $4.

Stock Performance in Context

Over the past year, CL shares have increased by 9.3%, outperforming both the S&P 500 Index’s ($SPX) 3.2% increase and the Consumer Staples Select Sector SPDR Fund’s (XLP) 8.4% return. Despite challenges posed by ongoing trade tensions and tariff policies implemented by President Trump, CL shares rose by 1.8% on April 9. The company has demonstrated its ability to remain a strong competitor in the consumer staples sector, which typically performs well during market uncertainty due to consistent demand for essential products.

Analyst Ratings and Market Sentiment

The consensus outlook on Colgate-Palmolive stock is moderately optimistic, currently holding an overall “Moderate Buy” rating. Out of 23 analysts covering the stock, 11 recommend a “Strong Buy,” two suggest a “Moderate Buy,” eight advocate for a “Hold,” and two assign a “Strong Sell” rating. The mean price target for CL stands at $99.04, indicating a potential upside of 5.4% from current price levels.

On the date of publication,
Kritika Sarmah
did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are solely for informational purposes. For further details, please view the Barchart Disclosure Policy
here.

 

More news from Barchart

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.